You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
No changes of cholesterol levels with a commercially available glucosamine product in patients treated with lipid lowering drugs: a controlled, randomised, open cross-over trial
|
---|---|
Published in |
BMC Pharmacology and Toxicology, October 2012
|
DOI | 10.1186/2050-6511-13-10 |
Pubmed ID | |
Authors |
Robert Eggertsen, Åke Andreasson, Lennart Andrén |
Abstract |
The widespread use of natural health products is also a problem, as they could interact with prescribed drugs in patients. One commonly used product is glucosamine for osteoarthritis and some reports have found increased values of cholesterol and other lipids in patients treated with simvastatin for hypercholesterolemia. The aim of this trial was to investigate the effects of glucosamine on s-cholesterol levels (total s-cholesterol, s-HDL, s-LDL) in primary care patients on treatment with simvastatin or atorvastatin. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | 33% |
United States | 1 | 17% |
Unknown | 3 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 83% |
Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 34 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 10 | 29% |
Researcher | 4 | 12% |
Other | 3 | 9% |
Student > Doctoral Student | 3 | 9% |
Student > Master | 2 | 6% |
Other | 2 | 6% |
Unknown | 10 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 24% |
Nursing and Health Professions | 5 | 15% |
Agricultural and Biological Sciences | 4 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Biochemistry, Genetics and Molecular Biology | 2 | 6% |
Other | 1 | 3% |
Unknown | 12 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 October 2012.
All research outputs
#8,052,473
of 24,337,175 outputs
Outputs from BMC Pharmacology and Toxicology
#146
of 462 outputs
Outputs of similar age
#58,431
of 175,677 outputs
Outputs of similar age from BMC Pharmacology and Toxicology
#4
of 11 outputs
Altmetric has tracked 24,337,175 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 462 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 175,677 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.